Chugai Pharmaceutical Stock And Two Japan Shares Trading Below Cash Flow Value

Weaker US payrolls have pushed government bond yields lower, which has lifted the present value of future cash flows for many companies. That shift is shining a light on stocks where cash flow potential and current share prices look out of sync. This article walks through three of the most interesting opportunities from the Undervalued Stocks Based On Cash Flows screener so you can decide whether they deserve a spot on your watchlist.

The stocks highlighted below are just a small sample, and the full screen surfaced 59 more companies with cash flow stories that are just as compelling but not covered here. To identify the ideas that best suit your style and risk tolerance, head straight into the Undervalued Stocks Based On Cash Flows screener.

Chugai Pharmaceutical (TSE:4519)

Chugai Pharmaceutical is a Japan based drug maker focused on cancer, autoimmune and rare disease treatments, selling a broad portfolio of biologic and antibody based therapies across Japan and international markets. It currently reports essentially all of its ¥1,342,808m revenue from pharmaceuticals, and sits in large cap territory with a market value of about ¥11,281b. That scale gives Chugai the resources to fund research while still returning cash to shareholders through dividends.

Investors looking for high quality cash flow stories may find Chugai Pharmaceutical worth a closer look. The company combines a deep biologics pipeline and Roche backed global reach with profitability metrics such as a 23.2% return on equity and 35.1% net margins, plus recent earnings momentum and higher 2026 guidance. At the same time, concentration in a few flagship drugs, an uneven dividend record and higher risk funding mean the story is not without complications. The recent push into AI driven drug discovery and new indications like Enspryng for MOGAD could be important pieces of the puzzle that are not yet fully reflected in the current share price.

Chugai Pharmaceutical’s rich margins and Roche partnership point to a cash engine that many investors may be underestimating. Scan the 3 key rewards and 1 important warning sign to see what could quietly change the story next.

Build your own cash flow shortlist around companies like Chugai Pharmaceutical

Chugai Pharmaceutical and the two other stocks in this article all surfaced from a single Simply Wall St screener, and you can set up the same kind of process for yourself. Use our customisable Screener to mix filters on valuation, cash flows, balance sheets, risks and dividends, or browse through our curated Investing Ideas for ready made stock shortlists that fit different approaches.

JX Advanced Metals (TSE:5016)

JX Advanced Metals is a Japan based materials company that develops and sells copper and rare metal products used in semiconductors, ICT hardware and recycling applications, from copper foils and sputtering targets to compound semiconductors and high purity metals. The company, founded in 1905 and headquartered in Minato, Tokyo, now sits firmly in large cap territory with a market value of about ¥3.7t.

JX Advanced Metals stands out on this cash flow focused screen because it links high quality earnings with clear signals about shareholder returns. Earnings grew over the past year, net margins sit at 14.6% and return on equity is above 20%, yet the stock still trades at a discount to one estimate of fair value. At the same time, funding the balance sheet entirely with higher risk borrowing and a relatively rich P/E multiple keep expectations high. The recent share buyback of more than 6% of issued capital and inclusion in major S&P indices add another layer for investors who value both liquidity and capital discipline, but these moves also raise questions about how repeatable current momentum might be.

JX Advanced Metals links high quality margins and buybacks with a P/E that already bakes in a lot. Review the 3 key rewards and 1 important major warning sign to evaluate whether that confidence masks a bigger twist in the story.

Murata Manufacturing (TSE:6981)

Murata Manufacturing is a global supplier of ceramic based electronic components that sit inside smartphones, cars, data centers and industrial equipment, offering everything from capacitors and inductors to sensors, batteries and wireless modules. Most of its roughly ¥2,030,000m in revenue comes from Components at about ¥1,250,550m and Devices and Modules at about ¥664,774m, with smaller contributions from Other activities. The company is firmly in mega cap territory with a market value of about ¥13,220.8b.

Murata Manufacturing brings together a broad component portfolio, high quality earnings and an earnings outlook that analysts expect to grow faster than both the Japanese market and the wider electronics sector. The stock screens as undervalued versus an estimate of its future cash flows despite a rich P/E, which suggests investors may be underpricing its guidance for higher revenue and profit into 2027. At the same time, a highly volatile share price and a balance sheet funded entirely by higher risk borrowing mean this is not a low drama story. If you are looking for a way to gain exposure to long term demand for electronics, especially in autos and data infrastructure, Murata’s mix of growth, income and funding risk is worth understanding in more depth before making an investment decision.

Murata Manufacturing’s cash flow story looks out of sync with its richer P/E, which suggests something in the earnings path might be getting overlooked. Review the analyst forecasts for Murata Manufacturing to see what could be quietly building beneath the volatility.

Seeking Fresh Alternatives Before They Fly

Fresh ideas can move from quiet to breakout quickly. Some stocks build momentum while the crowd is still looking elsewhere. Check these under the radar lists and consider them before they become widely followed.

• Target cash-generating stability with companies on the 43 dividend fortresses which focus on income strength that could hold up even when prices drop or volatility rises.
• Look for long-term structural trends by scanning the 55 AI infrastructure stocks where demand for compute power, data centers and supporting hardware may still be underappreciated by many investors.
• Search across sectors for resilient balance sheets through the list of solid balance sheet and fundamentals (40 results) and identify stocks that may be better positioned if weaker businesses face pressure during a downturn.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com